Management Sciences For Health’s (MSH) “Global Health Impact” blog on Friday published two posts examining the importance of good governance in health care. In the first post, Jonathan Quick, president and chief executive officer of MSH, writes, “Good governance in health care matters at all levels of the health system — from communities to health facilities to governments,” adding, “Effective management, inspiring leadership, and accountable governance are each vital for building strong health systems that achieve lasting local health impact” (6/22). In the second post, James Rice, project director of USAID’s Leadership, Management, & Governance (LMG) project, writes, “Policymakers and health sector leaders in low- and middle-income countries are recognizing the value of smart governance for significant and sustained gains in health status outcomes,” noting, “The new USAID [LMG] project, led by MSH with a consortium of partners, is actively engaged in building the capacity and competencies of those expected to accomplish smart governance” (6/22).
“As the international community engages in a last push to decrease child deaths annually from 12 million in 1990 to four million by 2015, world leaders [met] for the ‘Child Survival — Call to Action’ Summit in Washington, D.C., [earlier this month] to set an even more ambitious goal of ‘ending all preventable child deaths’ down to two million by 2035,” Kul Chandra Gautam, former deputy executive director of UNICEF, writes in this post in the Huffington Post’s “Global Motherhood” blog, adding, “This is a fitting moment for reflection and celebration of USAID’s 50th anniversary, and 30 years of historic contribution and leadership in what came to be known as a global Child Survival and Development Revolution (CSDR).”
In this post on RH Reality Check, Marianne Mollmann, senior policy adviser with Amnesty International, addresses an upcoming summit in London on family planning funding, which is being co-hosted by the Bill & Melinda Gates Foundation and the U.K. Department for International Development and supported by USAID and UNFPA. She says that poverty and “women’s ability to exercise her human rights, including the rights to quality health care, non-discrimination in education and health, and economic empowerment through job creation and protections for equality in the workplace,” are important drivers of maternal health and need to be addressed by governments (6/21).
Burma, also known as Myanmar, “seems to be making the difficult and fragile transition from military dictatorship to fledgling democracy,” but the country has “some of the worst health indicators in the world,” a Lancet editorial states. “[T]he military retains a strong presence in regions of ethnic tension, and health and human rights abuses are certain to continue without adequate monitoring,” it continues.
“Together with international partners, the United States has launched an unprecedented effort over the past three years to reverse a decades-long decline in agricultural investments,” with a goal of “alleviat[ing] the chronic hunger that afflicts nearly one billion people around the world, including an estimated 53 million in Latin America and the Caribbean,” a VOA editorial states. “In the Americas, Feed the Future invests in rural areas of three focus countries: Guatemala, Honduras and Haiti,” the editorial continues, noting, “Over five years, investments and programs involving the entire agricultural value chain from seeds to farms to markets will assist one million vulnerable women, children and family members, mostly smallholder farmers, to escape hunger and poverty in these countries.” The editorial states, “By working together, the United States believes [Organization of American States (OAS)] members can contribute collectively to food security at both the hemispheric and global levels. To achieve that goal, OAS members must safeguard the political and economic progress that has been made to date” (6/12).
While conducting more clinical trials in developing countries can help under-represented populations benefit from new medical developments, trials in low-income settings face challenges such as complicated regulations, Trudie Lang of the Centre for Tropical Medicine at the University of Oxford and Sisira Siribaddana of the University of Rajarata and the Institute of Research & Development in Sri Lanka write in an essay published Tuesday in PLoS Medicine (6/12). According to a PLoS press release, “The authors conclude: ‘the globalization of clinical trials should not be about running inexpensive trial sites to benefit distant people, but should focus on bringing research to populations who have previously been under-represented in clinical trials, and enabling these same communities the benefits resulting from new drugs, vaccines, and improvements in managing health'” (6/12).
HIV drugs have not only “transformed a fatal disease into a chronic one,” but “[t]hey have also made HIV a big business,” this Economist editorial states. The editorial examines the market for HIV drugs, writing, “The market is as unusual as it is large, both buoyed by government support and worryingly dependent on it. The past decade has brought fancier medicine in rich countries and copious aid for poor ones. But the war is far from won.” The editorial writes, “In total, public and private investment has yielded more than two dozen HIV drugs,” adding, “Sales of antiretroviral drugs in America and the five biggest European markets reached $13.3 billion in 2011, according to Datamonitor, a research outfit.”
In this post in the Huffington Post’s “World” blog, Cecilia Attias, former first lady of France and president and founder of the Cecilia Attias Foundation for Women, responds to a recent paper, published by the World Bank, which discusses significant declines in infant and under-five mortality in Kenya and across sub-Saharan Africa. She writes, “Africa’s swift economic growth has become a familiar story; but the fact that fewer children are dying than before — that people’s lives are getting better on the ground — is arguably more heartening than accounts of improvements in African industry or infrastructure or business (though the trends are probably connected).”
“One in 10 cases of tuberculosis in China cannot be treated by the most commonly-used drugs, driven by a lack of testing and misuse of medicine, according to a national survey that showed for the first time the size of the drug-resistant epidemic,” the Associated Press reports (Wong, 6/7). “‘In 2007, one third of the patients with new cases of tuberculosis and one half of the patients with previously treated tuberculosis had drug-resistant disease,’ said the study in the New England Journal of Medicine,” Agence France-Presse reports, adding, “Even more, the prevalence of multi-drug resistant [tuberculosis (MDR-TB)] in new cases (5.7 percent) was nearly twice the global average, said the study” (6/6).
Aid Agencies Should Support Journalists To Increase Their Ability To Make A Difference In Developing Countries
In this post in the Guardian’s “Poverty Matters” blog, Prue Clarke, an Africa correspondent, media development specialist and the co-founder and executive director of New Narratives — Africans Reporting Africa, writes, “By not supporting journalists, aid agencies are severely limiting their access to the truth about what is happening in developing countries and, therefore, their ability to make a difference.” She continues, “In our efforts to promote our reporters’ work and fund our operations, we repeatedly meet fantastic aid groups that are driven to improve the lives of poor people in Africa, particularly women,” adding, “They fund every manner of effort to, for example, end violence against women, improve maternal health, increase the number of girls in education and prevent exploitation by foreign resources companies.”